Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Antigen processing and presentation | R-HSA-1236975 | map04612 | pridinol | 4904 | drug-path |
| TGF-beta signaling pathway | R-HSA-168638 | map04350 | pridinol | 4904 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | pridinol | 4904 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | pridinol | 4904 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | hecogenin | 91453 | drug-path |
| Non-homologous end-joining | R-HSA-5693571 | map03450 | hecogenin | 91453 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | hecogenin | 91453 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | hecogenin | 91453 | drug-path |
| p53 signaling pathway | R-HSA-168638 | map04115 | hecogenin | 91453 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | hecogenin | 91453 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | pipenzolate bromide | 657306 | drug-path |
| Fc epsilon RI signaling pathway | R-HSA-2454202 | map04664 | pipenzolate bromide | 657306 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | pipenzolate bromide | 657306 | drug-path |
| Melanogenesis | R-HSA-5662702 | map04916 | pipenzolate bromide | 657306 | drug-path |
| Glioma | Q9NZM4 | map05214 | pipenzolate bromide | 657306 | drug-path |
| Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | pipenzolate bromide | 657306 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | pipenzolate bromide | 657306 | drug-path |
| Long-term potentiation | R-HSA-9620244 | map04720 | pipenzolate bromide | 657306 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | pipenzolate bromide | 657306 | drug-path |
| Vascular smooth muscle contraction | R-HSA-445355 | map04270 | pipenzolate bromide | 657306 | drug-path |